Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients [4]

Journal of Clinical Psychiatry

Volumn 67, Issue 7, 2006, Pages 1158-1159

  Crossman, Andrya M ^a   Lindenmayer, Jean Pierre ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; LITHIUM; VALPROIC ACID; ZIPRASIDONE;

AGITATION; ANAMNESIS; CATATONIC SCHIZOPHRENIA; DOSE RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSOMNIA; LETTER; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; SYMPTOMATOLOGY; WEIGHT REDUCTION;

EID: 33747187762     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v67n0721d     Document Type: Letter

References (2)

1. Kane J, Carson W, Kujawa M, et al. Aripiprazole vs perphenazine in treatment-resistant schizophrenia [poster]. Presented at the 156th annual meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif
2. Saha A, Ali MW, Ingenito GG, et al. Safety and tolerability of aripiprazole at doses higher than 30 mg. Int J Neuropsychopharmacol 2002;5(suppl 1):S185